Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

BMS’s acquisition of Orbital Therapeutics marks a deliberate push into autoimmune disease treatment via advanced cell therapy. Orbital, founded in 2022 by leaders in RNA and immunology, has built a proprietary RNA platform combining circular and linear RNA engineering with sophisticated lipid nanoparticle delivery Bms Fiercebiotech. Its lead program, OTX-201, is designed as an in vivo CAR‑T: instead of harvesting and engineering cells outside the body, Orbital will inject circular RNA encoding a CD19-directed CAR into the patient, so the patient’s own T cells become the “manufacturers” of CAR‑T cells in situ Bms Orbitaltx. This approach could greatly simplify CAR‑T therapy logistics. As BMS noted, it may “offer a reduced treatment burden and improved accessibility” relative to conventional ex vivo CAR‑T, which requires cell collection, manufacturing and intensive preparation Bms.